The emergence of the coronavirus 2019 (COVID-19) pandemic has presented an 
unprecedented global challenge. Vaccines against COVID have been developed to 
date. Covid-19 has been linked with the development of Guillain-Barre Syndrome 
(GBS), a rare immune-mediated demyelinating neuropathy. We report three cases of 
Guillain-Barre Syndrome and one case of Chronic Inflammatory Demyelinating 
Polyneuropathy (CIDP), presenting to a Tasmanian hospital, and review 15 other 
reported cases and discuss likely immunopathology. Nearly all reported cases of 
post-COVID-19 vacciation inflammatory demyelinating polyneuropathy are linked to 
AstraZeneca vaccination and a variant with bifacial weakness is the most 
reported form of GBS globally.